NASDAQ
EYPT

Eyepoint Pharmaceuticals Inc

LABORATORY ANALYTICAL INSTRUMENTS
LIFE SCIENCES

Prices are adjusted according to historical splits.

Eyepoint Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$4.8900
Today's High:
$5.6250
Open Price:
$5.4800
52W Low:
$4.89
52W High:
$21.5
Prev. Close:
$5.4200
Volume:
169436

Company Statistics

Market Cap.:
$0.175 billion
Book Value:
4.445
Revenue TTM:
$0.041 billion
Operating Margin TTM:
-170.9%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
-184.5%
Return on Assets TTM:
-21.5%
Return on Equity TTM:
-59.3%

Company Profile

Eyepoint Pharmaceuticals Inc had its IPO on 2005-01-27 under the ticker symbol EYPT.

The company operates in the LIFE SCIENCES sector and LABORATORY ANALYTICAL INSTRUMENTS industry. Eyepoint Pharmaceuticals Inc has a staff strength of 0 employees.

Stock update

Shares of Eyepoint Pharmaceuticals Inc opened at $5.48 at the start of the last trading session i.e. 2022-11-02.

The stocks traded within a range of $4.89 - $5.63, and closed at $5.13.

This is a -5.35% slip from the previous day's closing price.

A total volume of 169,436 shares were traded at the close of the day’s session.

In the last one week, shares of Eyepoint Pharmaceuticals Inc have slipped by -14.5%.

Eyepoint Pharmaceuticals Inc's Key Ratios

Eyepoint Pharmaceuticals Inc has a market cap of $0.175 billion, indicating a price to book ratio of 1.236 and a price to sales ratio of 4.216.

In the last 12-months Eyepoint Pharmaceuticals Inc’s revenue was $0.041 billion with a gross profit of $0.000 billion and an EBITDA of $-0.068 billion. The EBITDA ratio measures Eyepoint Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Eyepoint Pharmaceuticals Inc’s operating margin was -170.9% while its return on assets stood at -21.5% with a return of equity of -59.3%.

In Q2, Eyepoint Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 28.3%.

Eyepoint Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
-
Trailing PE
-
PEG
None

Its diluted EPS in the last 12-months stands at $-2.105 per share while it has a forward price to earnings multiple of - and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eyepoint Pharmaceuticals Inc’s profitability.

Eyepoint Pharmaceuticals Inc stock is trading at a EV to sales ratio of 1.456 and a EV to EBITDA ratio of -0.873. Its price to sales ratio in the trailing 12-months stood at 4.216.

Eyepoint Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Eyepoint Pharmaceuticals Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Eyepoint Pharmaceuticals Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Eyepoint Pharmaceuticals Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Eyepoint Pharmaceuticals Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Eyepoint Pharmaceuticals Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$5.13
52-Week High
$21.5
52-Week Low
$4.89
Analyst Target Price
$33.67

Eyepoint Pharmaceuticals Inc stock is currently trading at $5.13 per share. It touched a 52-week high of $21.5 and a 52-week low of $21.5. Analysts tracking the stock have a 12-month average target price of $33.67.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Eyepoint Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Eyepoint Pharmaceuticals Inc is EYPT

The IPO of Eyepoint Pharmaceuticals Inc took place on 2005-01-27

Similar Industry Stocks (LABORATORY ANALYTICAL INSTRUMENTS)

Last Price
Chg
Chg%
$10.25
-0.93
-8.32%
Illumina Inc (ILMN)
$210.98
-8.15
-3.72%
$61.08
-1.89
-3%
$0.48
-0.03
-5.61%
$2.68
-0.08
-2.9%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
$0.02
0.01
+100%
Oi S.A (OIBR-C)
$0
0
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.

Address

480 PLEASANT STREET, SUITE B300, WATERTOWN, MA, US